EIF4G2 was previously identified as a direct target of miR-139 in AML, with luciferase assays identifying binding sites in both the 3′UTR and 5′UTR, while in glioblastoma, only the 3′UTR binding site was validated with reporter assays and also anti-Ago2-mediated RNA-immunoprecipitation assays [46,54]. The gene discussed is EIF4G2; the disease is glioblastoma.